Over the past two decades, exploration of epileptic patients has benefited from technological advances in electroencephalography. Computerized equipment can simultaneously retrieve cerebral electric activity and signs of the patient's ictal activity. The computer era has improved reliability, storage and analysis of the recorded data and provides easier communication tools for multidisciplinary staff and patient case studies. Therefore, an increasing number of patients could benefit from presurgical investigations and surgical treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neuchi.2008.02.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aim: This study investigated the accuracy of intraoral scanner (IOS) based on different image acquisition technologies in the field of presurgical-orthopedictreatment (PSOT) in neonates with cleft.
Methods: Dental cast models of clinical situations representing unilateral cleft-lip-palate(UCLP), bilateral cleft-lippalate( BCLP) and cleft-palate(CP) with reference PEEK-scanbodies (Cares RC Mono-Scankörper, Straumann, Switzerland) were scanned utilizing four IOS systems: CareStream-CS3600®(CS), Medit-i500®(MD), Cerec-Omnicam®(SO), 3Shape-Trios-3®(TS). One calibrated operator made 5 scans from each model using each IOS (N=60).
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care.
J Immunother Cancer
January 2025
The Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.
Neoadjuvant (presurgical) anti-programmed cell death protein-1 (PD-1)-based immunotherapy as a new approach to cancer treatment has been developing on an accelerated trajectory since the seminal clinical trial results from studies in lung cancer and melanoma were published in 2018. Groundbreaking regulatory approvals in triple-negative breast cancer, non-small cell lung cancer and melanoma will certainly be followed by additional approvals in other disease indications, as clinical and basic research are burgeoning globally in hundreds of clinical trials across dozens of cancer types. As this field is evolving, it is addressing gaps in our understanding of biological mechanisms underlying PD-1 pathway blockade and their synergy with other antineoplastic drugs, probing mechanisms of response and resistance to neoadjuvant immunotherapy, optimizing efficacious clinical strategies, and analyzing commonalities and differences across cancer types.
View Article and Find Full Text PDFA Comparative Study Between Posterolateral Lumbar Fusion and Transforaminal Lumbar Interbody Fusion for Degenerative Lumbar Spondylolisthesis.
Cureus
December 2024
Department of Orthopedics, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, IND.
Introduction Degenerative spondylolisthesis (DS) is a degenerative condition characterized by subluxation of one vertebral body anterior to the adjacent inferior vertebral body with an intact pars. Conservative treatment approaches, such as steroid injections and physical therapy, may work well at first, but in resistant situations, surgery is frequently necessary. Posterolateral lumbar fusion (PLF) has been widely used, but transforaminal lumbar interbody fusion (TLIF) offers theoretical advantages such as improved alignment and enhanced fusion rates.
View Article and Find Full Text PDFAssociation of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer.
Eur J Cancer
January 2025
Department of Thoracic and Cardiovascular Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Patient-Centered Outcomes Research Institute, Samsung Medical Center, Seoul, South Korea; Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea. Electronic address:
Background: Sublobar resection is increasingly recognized as an effective treatment for early-stage NSCLC. However, no studies to date have investigated the potential role of preoperative ctDNA detection in guiding surgical decisions, such as opting for sublobar resection, in stage I NSCLC.
Methods: Patients with solid-dominant (CTR>0.
Tumour volume analysis applied to imaging and histological examinations in breast cancer.
Eur J Surg Oncol
January 2025
Imperial College Healthcare Trust, Fulham Palace Road, London, W6 8RF, England, UK. Electronic address:
Purpose: Response Evaluation Criteria in Solid Tumours (RECIST) determines partial response (PR) and progressive disease (PD) as a 30 % reduction and 20 % increase in the longest diameter (LD), respectively. Tumour volume analysis (TVA) utilises three diameters to calculate response parameters.
Patients And Methods: We conducted a pilot investigation of patients who underwent neoadjuvant breast cancer treatment and evaluation using RECIST with LD measurements and TVA with three diametric measurements, using the parameters PR (>30 % tumour regression), PD (>20 % tumour growth), and intermediate stable disease (SD).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!